Centers | ||
Presude Life Sciences | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
Sanofi and Weill Cornell Medical College to Discover New Drus to Treat TuberculosisSanofi has entered into a new collaboration with Dr.Carl Nathan's laboratory at Weill Cornell Medical College to screen existing compounds and develop new compounds to shorten the course of treatment of tuberculosis and increase effectiveness of... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all UCB Partners with Oxford UniversityUCB has entered into a research and development partnership with Oxford University in Neurology and Immunology areas. UCB will provide 3.6 million pounds to Oxford scientists over a period of three year to conduct research. View all |
No EVENTS for listing |
No Job Posts |


